ReviewCNS & neurological disorders drug targets2010
Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.
Review in CNS & neurological disorders drug targets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- The role of nicotinic receptors in alcohol consumption.Pharmacological research · 2023Pooled it
- Effectiveness of Varenicline and Cytisine for Alcohol Use Reduction Among People With HIV and Substance Use: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Pilot investigation: randomized-controlled analog trial for alcohol and tobacco smoking co-addiction using contingency management.Behavioural pharmacology · 2018Trial
- Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
- Mecamylamine treatment for alcohol dependence: a randomized controlled trial.Addiction (Abingdon, England) · 2018Trial
- Reduced brain network segregation in alcohol use disorder: Associations with neurocognition.Addiction biology · 2024Article
- A Little "Re-Cognition" Goes a Long Way for Pro-Cognitive Therapeutics in Alcohol Studies.The Journal of pharmacology and experimental therapeutics · 2024Article
- Cognitive-Enhancing Effects of Acetylcholine Receptor Agonists in Group-Housed Cynomolgus Monkeys Who Drink Ethanol.The Journal of pharmacology and experimental therapeutics · 2024Article
- Both Moderate and Heavy Alcohol Use Amplify the Adverse Cardiovascular Effects of Smoking in Young Patients with Hypertension.Journal of clinical medicine · 2023Article
- Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats.Frontiers in pharmacology · 2023Article
- Alcohol, nicotine, and COVID-19: A retrospective study of health outcomes in central Pennsylvania.Brain research bulletin · 2023Article
- Assessing the association between smoking and hypertension: Smoking status, type of tobacco products, and interaction with alcohol consumption.Frontiers in cardiovascular medicine · 2023Article
- UFR2709, an Antagonist of Nicotinic Acetylcholine Receptors, Delays the Acquisition and Reduces Long-Term Ethanol Intake in Alcohol-Preferring UChB Bibulous Rats.Biomedicines · 2022Article
- Association between Drinking Patterns and Incident Hypertension in Southwest China.International journal of environmental research and public health · 2022Article
- The incentive amplifying effects of nicotine: Roles in alcohol seeking and consumption.Advances in pharmacology (San Diego, Calif.) · 2022Review
- The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials.Addictive behaviors · 2021Article
- The role of nicotinic acetylcholine receptors in alcohol-related behaviors.Brain research bulletin · 2020Review
- Role of mPFC and nucleus accumbens circuitry in modulation of a nicotine plus alcohol compound drug state.Addiction biology · 2020Article
- The Paradox Association between Smoking and Blood Pressure among Half Million Chinese People.International journal of environmental research and public health · 2020Article
- Brain Structure and Function in Recovery.Alcohol research : current reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alcohol use disorders (AUDs) are complex, and developing effective treatments will require the combination of novel medications and cognitive behavioral therapy approaches. Epidemiological studies have shown there is a high correlation between alcohol consumption and tobacco use, and the prevalence of smoking in alcoholics is as high as 80% compared to about 30% for the general population. Both preclinical and clinical data provide evidence that nicotine administration increases alcohol intake and non-specific nicotinic receptor antagonists reduce alcohol-mediated behaviors. As nicotine interacts specifically with the neuronal nicotinic acetylcholine receptor (nAChR) system, this suggests that nAChRs play an important role in the behavioral effects of alcohol. In this review, we discuss the importance of nAChRs for the treatment of AUDs and argue that the use of FDA approved nAChR ligands, such as varenicline and mecamylamine, approved as smoking cessation aids may prove to be valuable treatments for AUDs. We also address the importance of combining effective medications with behavioral therapy for the treatment of alcohol dependent individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.